Company news

Xilio Therapeutics, Inc. news in 2025

Xilio Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

November 13, 2025

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

November 7, 2025

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

November 7, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 3, 2025

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

October 30, 2025

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

October 3, 2025

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

September 9, 2025

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

August 14, 2025

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

August 4, 2025

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

June 10, 2025

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

June 5, 2025

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

June 2, 2025

Xilio Therapeutics Announces Proposed Public Offering

June 2, 2025

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 31, 2025

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

April 23, 2025

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

March 11, 2025

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

February 24, 2025

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

February 11, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 2, 2025

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

January 20, 2025

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 9, 2025

Decks in 2025